PHASE-1-2 EVALUATION OF CYCLOCYTIDINE

  • 1 January 1977
    • journal article
    • research article
    • Vol. 61  (3) , 437-443
Abstract
A phase I-II study of cyclocytidine was conducted in 102 patients, 96 of whom had metastatic solid tumors and 6 of whom had acute leukemia. The drug was administered in 5- or 10-day courses of single daily i.v. or s.c. injections of 100-675 mg/m2 per day. Two complete and 6 partial responses were observed in 64 solid tumor patients evaluable for response, 52 of whom had malignant melanoma or adenocarcinoma of gastrointestinal origin. The median duration of the responses was 6 mo. An additional 7 patients achieved stabilization of their disease for .gtoreq. 2 mo. No responses occurred in 6 patients with acute leukemia. Side effects included nausea and vomiting, postural hypotension and parotid pain, occurring in .apprx. 1/3 of patients receiving > 200 mg/m2 per day. No myelosuppression was observed in 6 patients receiving 5-day courses of 100-200 mg/m2 per day. Myelosuppressive toxicity became increasingly severe with doses > 200 mg/m2 per day .times. 10, related at least in part to prior chemotherapy exposure including the nitrosoureas.

This publication has 0 references indexed in Scilit: